CheckMate914
Descrição
![CheckMate914](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2021/nejm_2021.385.issue-8/nejmoa2106391/20210818/images/img_medium/nejmoa2106391_f0.jpeg)
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
![CheckMate914](https://i0.wp.com/gantaisaku.net/wp-content/uploads/2023/02/29537203569ba5df76e80050b988ed8a.png?resize=678%2C381&ssl=1)
日本がん対策図鑑 【腎細胞がん:術後治療(DFS)】「オプジーボ+ヤーボイ」vs「経過観察」
![CheckMate914](https://www.cancerresearchuk.org/sites/default/files/styles/cruk_wide_resp_breakpoint_one/public/16963-part-a-randomisation.png?itok=PTjBfja2)
A trial of nivolumab with or without ipilimumab after surgery for kidney cancer (CheckMate 914)
![CheckMate914](https://assets.delveinsight.com//products/infographics/1613648851-Cervical-Cancer-Market-Infographic.jpg)
CheckMate-914 trial's disappointing results cast doubt on BMS's plans to advance PD-1 inhibitors
![CheckMate914](https://www.clinical-genitourinary-cancer.com/cms/asset/04eec5a8-0302-4a7f-9750-e2a43f414ba1/gr2.jpg)
Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States - Clinical Genitourinary Cancer
![CheckMate914](https://pbs.twimg.com/media/Fx4V5j3XgAEfImR.jpg)
Toni Choueiri, MD on X: Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC
![CheckMate914](https://www.urotoday.com/images/EAU2019_Checkmate_914_study_sites.png)
EAU 2019: Post-Nephrectomy Adjuvant Therapy for Localized Renal Cell Carcinoma: CheckMate 914 Study of Nivolumab + Ipilimumab in Patients at High Risk of Relapse
ASCO GU 2022: Updates on Clinical Trials in Adjuvant Renal Cell Carcinoma
![CheckMate914](https://pbs.twimg.com/media/FY2KXxuUcAUdjnK.jpg)
ScienceLink on X: #Nivolumab #Ipilimumab #CheckMate914 #ScienceLink CCR localizado: Nivolumab + ipilimumab no alcanzaron objetivo primario de SLE, estudio CheckMate-914 / X
![CheckMate914](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41585-020-0282-3/MediaObjects/41585_2020_282_Fig2_HTML.png)
Checkpoint inhibitor immunotherapy in kidney cancer
![CheckMate914](https://cdn.sanity.io/images/0vv8moc6/onclive/d7e0d488885995713c1b1ea22f0517d7f14cacfa-1313x1688.jpg?fit=crop&auto=format)
Adjuvant Nivolumab/Ipilimumab Fails to Meet DFS End Point in Localized RCC
![CheckMate914](https://kidney-cancer-journal.com/img/cancer/bms_logo.jpg)
CheckMate914
![CheckMate914](https://pbs.twimg.com/media/Fx4WMFMWAAEGXj_.jpg)
Toni Choueiri, MD on X: Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC
![CheckMate914](https://www.urotoday.com/images/SIU19_rcc_trials2.png)
SIU 2019: Adjuvant Therapy for High-risk Renal Cell Carcinoma: Current Status
de
por adulto (o preço varia de acordo com o tamanho do grupo)